GermanoGiovanni University of MilanoItaly

Giovanni Germano, Ph.D., is an associate professor at the Department of Medical Biotechnologies and Translational Medicine at the University of Milano. In 2011, he earned his Ph.D. in basic and applied immunology while working with a cutting-edge group focused on inflammation and cancer. His research involved studying the in vivo effects of a registered compound, trabectedin, on tumor-associated macrophages. After completing his postdoc at the University Hospital of Zurich, he now leads an immune-oncology research team in Professor Bardelli's laboratory. His groundbreaking discovery revealed that altering DNA repair pathways in cancer triggers immune surveillance when combined with immune checkpoint blockades. Building on previous validation studies described in Nature, he co-founded NeoPhore LTD, a company dedicated to identifying chemical compounds capable of inhibiting DNA damage repair pathways.